PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 50
Summary
- Conditions
- Peripheral T Cell Lymphoma
- Type
- Interventional
- Phase
- Phase 4
- Design
- Intervention Model: Parallel AssignmentIntervention Model Description: 50 patients for newly diagnosed group and 50 patients for relapse/refractory group.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 14 years and 65 years
- Gender
- Both males and females
Description
Patients with peripheral T-cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully with the conventional CHOP regimen. The investigators have been proceeding this trial to evaluate the efficacy and safety of the PD-1, chidamide, lenalidomide and gemcitabine in the t...
Patients with peripheral T-cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully with the conventional CHOP regimen. The investigators have been proceeding this trial to evaluate the efficacy and safety of the PD-1, chidamide, lenalidomide and gemcitabine in the treatment of newly diagnosed and relapse/refractory peripheral T-cell lymphoma.
Tracking Information
- NCT #
- NCT04040491
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon